Altimmune (NASDAQ:ALT) Given “Buy” Rating at B. Riley Financial

Altimmune (NASDAQ:ALT)‘s stock had its “buy” rating restated by investment analysts at B. Riley Financial in a note issued to investors on Friday, Benzinga reports.

ALT has been the topic of a number of other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Altimmune in a report on Monday, September 21st. HC Wainwright restated a “buy” rating on shares of Altimmune in a report on Tuesday, July 28th. Finally, Evercore restated an “outperform” rating on shares of Altimmune in a report on Wednesday, September 23rd. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Altimmune presently has an average rating of “Moderate Buy” and a consensus price target of $14.00.

Altimmune Stock Up 0.3%

NASDAQ:ALT opened at $1.62 on Friday. Altimmune has a 12-month low of $1.60 and a 12-month high of $6.44. The company has a quick ratio of 26.78, a current ratio of 26.78 and a debt-to-equity ratio of 0.07. The firm has a market capitalization of $314.15 million, a P/E ratio of -2.07 and a beta of 0.16. The stock’s fifty day simple moving average is $2.62 and its 200-day simple moving average is $3.17.

Altimmune (NASDAQ:ALT) last issued its earnings results on Thursday, November 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). Equities research analysts expect that Altimmune will post -0.58 earnings per share for the current year.

Hedge Funds Weigh In On Altimmune

Institutional investors and hedge funds have recently made changes to their positions in the company. R Squared Ltd grew its position in Altimmune by 99.6% during the 3rd quarter. R Squared Ltd now owns 26,475 shares of the company’s stock worth $76,000 after purchasing an additional 13,211 shares during the period. StoneX Group Inc. purchased a new stake in shares of Altimmune during the 3rd quarter worth about $46,000. Parallel Advisors LLC boosted its stake in shares of Altimmune by 21,755.0% during the 3rd quarter. Parallel Advisors LLC now owns 8,742 shares of the company’s stock worth $25,000 after acquiring an additional 8,702 shares in the last quarter. Alps Advisors Inc. boosted its stake in shares of Altimmune by 29.6% during the 3rd quarter. Alps Advisors Inc. now owns 255,875 shares of the company’s stock worth $732,000 after acquiring an additional 58,501 shares in the last quarter. Finally, IPG Investment Advisors LLC purchased a new position in Altimmune in the 3rd quarter valued at about $29,000. Institutional investors and hedge funds own 78.05% of the company’s stock.

Top Altimmune Stories

These are some of the ALT stories that stood out recently:

• Positive Sentiment: Results published from the 48-week Phase 2b IMPACT study showed significant improvements versus placebo across measures of liver fat, inflammation and fibrosis, alongside weight loss and generally favorable tolerability. The findings support development of pemvidutide for MASH, though the drug remains investigational. Altimmune announces IMPACT Phase 2b 48-week data
• Positive Sentiment: Altimmune reported $480 million in cash, cash equivalents and investments as of September 30. A report said the balance is expected to fund operations through 2029, easing—but not eliminating—near-term financing concerns as key trials advance. Altimmune outlines cash runway and trial milestones
• Negative Sentiment: Altimmune reported a Q3 loss of $0.15 per share, missing the $0.13 loss expected by analysts. Higher R&D spending weighed on results, and continued investment in clinical programs leaves the company dependent on its cash runway and future trial success. ALT Q3 earnings miss, higher costs and funding concerns

Altimmune Company Profile

Altimmune, Inc. is a clinical-stage biopharmaceutical company developing peptide-based treatments for obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland. Its lead candidate, pemvidutide, is an investigational medicine that activates GLP-1 and glucagon receptors. Altimmune has studied the drug for obesity and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. Altimmune’s work focuses on advancing treatments through clinical development; pemvidutide is not an approved medicine.